Kintara Therapeutics Inc (KTRA): NEWS -- Kintara Therapeutics, Inc.: Invi...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Kintara Therapeutics Inc (KTRA)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	94
Posts	11188
Boards Moderated	0
Alias Born	11/02/2003

Re: None

Tuesday, 05/11/2021 7:15:55 AM

Tuesday, May 11, 2021 7:15:55 AM

NEWS -- Kintara Therapeutics, Inc.: Invitation to the Q2 Virtual Investor Summit

San Diego, California--(Newsfile Corp. - May 11, 2021) - Kintara Therapeutics, Inc. (NASDAQ: KTRA) today announced that Saiid Zarrabian, President & CEO will be attending the Q2 Virtual Investor Summit.

Event: Q2 Investor Summit
Date: May 17-18th, 2021
Presentation: May 18th at 11:00am ET
Location: https://zoom.us/webinar/register/WN_CaBoy6ovRySXUDmri34bUA

About Kintara Therapeutics, Inc.

Kintara (NASDAQ: KTRA) is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs. Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).

For further information:

Kintara Therapeutics, Inc.
Jules Abraham
917-885-7378
mailto://julesa@coreir.com

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit will take place virtually, featuring 80+ companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at https://www.investorsummitgroup.com

Contact:

Sasha Murray at mailto://sasha@investorsummitgroup.com

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent KTRA News

Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm • PR Newswire (US) • 04/05/2024 05:09:00 PM
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement • PR Newswire (US) • 04/03/2024 11:00:00 AM
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab • PR Newswire (US) • 03/27/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:59:49 AM
Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:00:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:10 PM
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:07:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:05:27 PM
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer • PR Newswire (US) • 02/12/2024 02:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:10:10 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/18/2023 09:05:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:15:08 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 02:10:19 PM
Kintara Therapeutics Announces Review of Strategic Alternatives • PR Newswire (US) • 12/07/2023 02:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 02:10:08 PM
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement • PR Newswire (US) • 12/05/2023 02:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2023 12:55:37 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:15:23 PM
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 11/13/2023 09:10:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 12:10:08 PM
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study • PR Newswire (US) • 10/31/2023 12:00:00 PM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/27/2023 08:05:48 PM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/24/2023 08:43:48 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 08:06:50 PM

More KTRA News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow